[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menstrual-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menstrual-symptoms":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100648034","mindfulness-based-education-for-women-with-polycystic-ovary-syndrome-100648034",false,"NCT07718217","Mindfulness-Based Education For Women With Polycystic Ovary Syndrome","The Effect Of Mindfulness-Based Education For Women With Polycystic Ovary Syndrome On Menstrual Symptoms, Stress, And Quality of Life: A Randomized Controlled Study","Inclusion Criteria:\n\n* Self-identify as female.\n* Be of reproductive age (18-49 years).\n* Have a confirmed diagnosis of Polycystic Ovary Syndrome (PCOS) based on the Rotterdam criteria.\n* Be able to read, understand, and communicate in Turkish.\n* Have access to the internet and a device capable of participating in online education sessions.\n\n  * Be willing to attend the four-week online education program and complete all study assessments.\n  * Provide written informed consent before participation.\n\nExclusion Criteria:\n\n* Currently pregnant or breastfeeding.\n* Having a severe psychiatric disorder or cognitive impairment that may interfere with participation.\n* Having a serious chronic medical condition that could affect study outcomes or prevent participation in the intervention.\n* Currently participating in another interventional research study.\n* Having previously received structured mindfulness training or participated in a mindfulness-based program during the study period.\n* Being unable to attend the online education sessions or complete the study assessments.\n* Declining or withdrawing informed consent at any stage of the study.",true,"FEMALE","18 Years","49 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"NA","Polycystic ovary syndrome (PCOS), also known as polyendocrine metabolic ovarian syndrome (PMOS), is the most common endocrinologic disorder to affect women. Despite this, the disease's pathophysiology remains unclear. This has hindered the diagnosis of the disease and the appropriate treatment for millions of individuals. The long-term health sequelae associated with PCOS, future directions, and areas of needed research in this often-overlooked disease. Women with PCOS may experience menstrual symptoms, increased stress, and difficulties in managing the physical and emotional effects of the condition. Supportive approaches that improve symptom management and quality of life may be beneficial in addition to routine care.\n\nThe aim of this randomized controlled study is to evaluate the effect of mindfulness-based PCOS education on menstrual symptoms, stress levels, and quality of life in women with PCOS. The study will examine whether a structured mindfulness-based education program can support women in managing PCOS-related symptoms and improving their overall well-being.\n\nWomen diagnosed with PCOS who meet the study eligibility criteria will be invited to participate. Participants will be randomly assigned to either the intervention group or the control group. Participants in the intervention group will receive a mindfulness-based PCOS education program, while those in the control group will receive routine care without it.\n\nResearchers will assess participants' menstrual symptoms, stress levels, and quality of life using validated measurement tools before and after the intervention. The findings of this study will provide information about the potential role of mindfulness-based education as a supportive approach in the management of PCOS and may contribute to the development of patient-centered education programs for women with PCOS.",[28,29,30,31],"Polycystic Ovary Syndrome (PCOS)","Menstrual Symptoms","Stress","Quality of Life",[33,34,35,36,29,37,38,31],"Polycystic Ovary Syndrome","PCOS","Mindfulness-Based Education","Mindfulness","Menstrual Pain","PCOS-Specific Quality of Life","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-07-20",{"date":47,"type":22},"2026-12",{"name":49,"class":50},"Aydin Adnan Menderes University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":70,"locationsCount":51},"100566303","the-nabu-effect-on-menstruation-in-women-100566303","NCT06653426","The NaBu Effect on Menstruation in Women","The Effect of Sodium Butyrate on Menstrual Symptoms in Women","Inclusion Criteria:\n\n* 18 years or older.\n* Menstruating regularly or irregularly\n* Experiencing menstrual symptoms with an average baseline symptom score of at least 3 on a scale of 0 to 10 for at least one symptom during the initial pre-study rating period.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding patient, attempting or anticipating pregnancy.\n* Patient with a history of bloating or a sensitive gut (food intolerance) who needs lower fiber levels.\n* Patients with known lactose intolerance, other fermentable oligo-, di-, and mono-saccharides, and polyols (FODMAP) intolerances, or small intestinal bacterial overgrowth (SIBO).\n* Patients who would require taking daily antacids for the duration of the study.\n* Patients with known or suspected chronic hypertension.\n* Post-menopausal patients",{"count":60,"type":22},15,[25],"The purpose of this study is to evaluate the effect of once-daily Sodium butyrate (NaBu) on menstrual symptoms in women. The investigators posit that the use of NaBu will reduce menstrual symptoms after taking NaBu for 12 weeks.",[29],"2026-04-23",{"date":66,"type":43},"2026-04-29",{"date":68,"type":43},"2024-10-01",{"date":47,"type":22},{"name":71,"class":50},"Magdy Milad, MD",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":103},"100633252","effera-dose-response-womens-health-100633252","NCT07524270","Effera Dose Response: Women's Health","Dose-Response of Effera® Supplementation for Women's Health Outcomes","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n* Women, 18 - 40 years of age\n* No changes in hormonal contraception use in the past 6 months\n* Regular or mildly irregular cycles (24-45 days) for the past 3 months\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience menstrual cramps on a pain scale of at least 4 out of 10 (1=no pain at all and 10 = worst pain ever experienced)\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience pain so significant that it requires over-the-counter pain medication for at least 2 days (on average) per period\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience at least one day per cycle where menstrual symptoms either interfere with work or school performance, limit normal daily activities or exercise, or lead to staying home, leaving early, or modifying plans\n* Reports noticeable mood or physical changes in the 5-7 days before menses in most cycles (irritability, mood, bloating, breast tenderness, cravings, sleep changes, etc.)\n* Generally healthy and free of diseases or disorders that impact functioning of the gastrointestinal system.\n* No recent or acute infection in the past 30 days and no chronic systemic illness\n* No psychiatric condition that, in the investigator's judgment, would impair consent capacity, protocol adherence, or valid completion of questionnaires.\n* If psychiatric medication is used: stable regimen for ≥3 months with no anticipated changes during the study\n* Body mass index (BMI) 18.5 to 32.5 kg\u002Fm2 (Inclusive)\n* Non-smoker\n* Agrees to not use any new vitamin, mineral, or dietary supplement product until after study completion and to not take any vitamins, minerals or dietary supplements 24 hours prior to the exercise test visits.\n* Willing and able to maintain consistent diet and physical activity habits\n* Willing and able to provide consent and comply with the protocol\n* Access to a smartphone, electronic, or personal computer with access to the internet to allow for completion of all online instruments and study reporting\n* Able to read and understand English at the 6th-grade level and sign the informed consent to participate in the study\n* Willing to use reliable contraception or maintain sexual abstinence during the study\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\n* Current or prior diagnosis from a licensed medical provider of Premenstrual Dysphoric Disorder (PMDD) or Premenstrual Syndrome (PMS) requiring ongoing medical or psychiatric treatment.\n* History of any food allergies or intolerances that could impact digestive outcomes and history of irritable bowel syndrome, inflammatory bowel disease (Crohn's, ulcerative colitis, celiac), gastroparesis, chronic constipation or diarrhea requiring medication, or GI surgery\n* Has any of the following medical conditions: bleeding disorders, active heart or cardiovascular disease, uncontrolled high blood pressure (≥ 140\u002F90 mmHg), renal or hepatic impairment\u002Fdisease, Type I or II diabetes, any neurologic disease or disorder that may impact cognition or mood, unstable thyroid disease, chronic inflammatory conditions, immune disorders (such as HIV\u002FAIDS), or any medical condition deemed exclusionary by the Principal Investigator (PI)\n* Acute illness or infection within the past 30 days\n* History of cancer (except localized skin cancer without metastases) within 5 years prior to screening.\n* Recently started taking (within the past 90 days or has had their dosage adjusted in the past 90 days) antihypertensives, hypoglycemic medications, GLP1 agonists of any class or type, stimulatory asthma medications, or any other prescription or over-the-counter medication that confound the outcomes measured in this study\n* Habitual use of anti-inflammatory medications for 30 days prior to providing consent\n* Current or past diagnosis of bipolar I\u002FII disorder, schizophrenia spectrum or other psychotic disorder; psychiatric hospitalization, suicidal ideation, attempt, or self-harm behavior in the past 12 months\n* Initiation, discontinuation, or dose change of any psychotropic medication within the past 3 months, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, stimulants, or sedative-hypnotics\n* Subject has an allergy to any ingredients in the study product\n* Subject has a history of drug or alcohol abuse in the past 12 months\n* Excessive alcohol intake defined as greater than 7 drinks\u002Fweek or binge episodes\n* Any condition or abnormality that in the expert opinion of the PI, participation in the study would compromise the safety of the subject or the quality of the study data.\n* Participating in or has participated in another research study within 30 days prior to the screening visit that could confound outcomes\n* Currently pregnant or lactating\n* Currently in prison, custody, or otherwise considered a ward of the state preventing their ability to free participate","40 Years",{"count":81,"type":22},160,[25],"The goal of this clinical trial is to learn if a human equivalent lactoferrin supplement (effera®) can improve menstrual symptoms, mood, and quality of life in healthy women aged 18-40.\n\nThe main questions it aims to answer are:\n\nDoes effera® reduce the severity of menstrual symptoms?\n\nDoes effera® improve mood, gastrointestinal symptoms, and overall well-being?\n\nResearchers will compare three different doses of effera® to a placebo (a look-alike supplement with no active ingredient) to see if the supplement improves these outcomes.\n\nParticipants will:\n\nTake the assigned supplement (effera® or placebo) daily for 12 weeks\n\nComplete online questionnaires about menstrual symptoms, mood, and health\n\nOptionally share sleep and activity data from a wearable device",[85,29],"Womens Health",[87,88,89,90,91,92,93],"Lactoferrin","Menstrual health","Dysmenorrhea","Effera","Gastrointestinal symptoms","Mood","Quality of life","2026-04-06",{"date":96,"type":43},"2026-04-13",{"date":98,"type":22},"2026-04",{"date":47,"type":22},{"name":101,"class":102},"Helaina Inc.","INDUSTRY",2]